Retifanlimab and Ruxolitinib In Solid Malignancies

This study is testing a combination of two drugs — retifanlimab (an immunotherapy that helps the immune system fight cancer) and ruxolitinib (a drug that blocks certain signals that help cancer evade the immune system) — in people with advanced kidney cancer (clear cell renal cell carcinoma) or non-small cell lung cancer whose cancer progressed after prior immunotherapy. **You may be eligible if...** - You have advanced clear cell renal cell carcinoma (kidney cancer) or non-small cell lung cancer (NSCLC) that progressed on or after prior PD-1/PD-L1 immunotherapy treatment - Your cancer can be measured on a scan - You are generally well enough for treatment (ECOG performance status 0 or 1) - You have adequate organ function (kidney, liver, and blood counts within safe ranges) - You are willing to take oral medication and comply with the study **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have not previously been treated with a PD-1/PD-L1 immunotherapy - You have already received more than one prior line of immunotherapy - You have not received any Janus kinase (JAK) inhibitor treatment previously (as prior JAK inhibitor use is required) Talk to your doctor to see if this trial is right for you.